Oncopeptides AB (ONCO) — Cash Flow-to-Debt Ratio
Oncopeptides AB (ONCO) has a Cash Flow-to-Debt Ratio of -1.12x as of December 2025, meaning its operating cash flow of Skr-216.49 Million could theoretically repay -1% of its total liabilities (Skr193.73 Million) in one year. See Oncopeptides AB (ONCO) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Oncopeptides AB Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Oncopeptides AB across 12 annual periods. Also explore Oncopeptides AB equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Oncopeptides AB (2014–2025)
Year-by-year debt coverage analysis for Oncopeptides AB. For market capitalisation and broader financial context, see ONCO market cap.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.15x | Skr-222.88 Million | Skr193.73 Million | ▲ +16.2% |
| 2024 | -1.37x | Skr-260.57 Million | Skr189.91 Million | ▲ +10.8% |
| 2023 | -1.54x | Skr-279.49 Million | Skr181.60 Million | ▲ +66.7% |
| 2022 | -4.62x | Skr-420.51 Million | Skr91.03 Million | ▲ +30.4% |
| 2021 | -6.64x | Skr-1.52 Billion | Skr228.51 Million | ▼ -89.3% |
| 2020 | -3.51x | Skr-1.30 Billion | Skr369.86 Million | ▲ +0.3% |
| 2019 | -3.51x | Skr-690.57 Million | Skr196.47 Million | ▼ -35.5% |
| 2018 | -2.59x | Skr-333.73 Million | Skr128.70 Million | ▲ +41.0% |
| 2017 | -4.39x | Skr-271.50 Million | Skr61.82 Million | ▼ -23.4% |
| 2016 | -3.56x | Skr-104.26 Million | Skr29.30 Million | ▲ +52.8% |
| 2015 | -7.54x | Skr-52.81 Million | Skr7.00 Million | ▼ -32.4% |
| 2014 | -5.70x | Skr-31.44 Million | Skr5.52 Million | — |